TG Therapeutics, Inc.

NasdaqCM:TGTX Rapporto sulle azioni

Cap. di mercato: US$3.6b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

TG Therapeutics Dividendo

Dividendo criteri di controllo 0/6

TG Therapeutics non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore2.0%
Prossima data di pagamento dei dividendin/a
Data di stacco del dividendon/a
Dividendo per azionen/a
Utile per azioneUS$0.67
Previsione del rendimento del dividendo a 3 anni0%

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 09
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback

Aug 07

TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet

Aug 02
TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet

Hold TG Therapeutics For Intriguing Outcomes

Jun 12

TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement

May 29
TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement

TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 04
TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

TG Therapeutics: Less Room For Doubt About Briumvi

May 03

News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

May 03
News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

Mar 25
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

TG Therapeutics: Briumvi Growth Story Appears Intact

Mar 01

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Jan 10

Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Jan 04
Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

Nov 24
Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Sep 30
TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Aug 03
Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jul 19
Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Apr 13
Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

Jan 02
Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

TG Therapeutics: Elucidating The Upcoming Binary

Oct 09

TG Therapeutics: We Are Just Hanging In There

Sep 21

Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

Sep 07
Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials

Aug 25

TG Therapeutics Q2 2022 Earnings Preview

Aug 05

TG Therapeutics And Ublituximab: From Icing To Lifeline

Jul 08

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jun 06
Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di TGTX siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di TGTX siano aumentati.


Rendimento dei dividendi rispetto al mercato

TG Therapeutics Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di TGTX rispetto al mercato?
SegmentoRendimento dei dividendi
Azienda (TGTX)n/a
Fondo del 25% del mercato (US)1.4%
Top 25% del mercato (US)4.5%
Media del settore (Biotechs)2.0%
Previsione dell'analista in 3 anni (TGTX)0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di TGTX rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di TGTX rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.


Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di TGTX per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.


Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché TGTX non ha segnalato alcun pagamento.


Scoprire le società che pagano dividendi forti